Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, has announced the opening of its new production facility in the Palava Industrial and Logistics Park at Taloja, Mumbai. The facility will increase manufacturing capabilities in South East Asia.

This expansion, which began in early 2022, is in line with Aptar’s localization strategy, and is a direct response by Aptar Pharma to growing customer demand in the region. Assembly operations and product delivery to customers have already begun at Aptar Mumbai’s new 7,000 m2 state-of-the art site, which has also received ISO 15378 certification.

"Our Aptar Pharma business in India has shown robust growth in recent years, and today marks yet another milestone in our investment in the South East Asia region,” commented Gael Touya, President, Aptar Pharma. “Over the past 11 years, Aptar Mumbai has continuously supplied safe, high-quality products that meet even the highest of regulatory requirements. This new facility is a key step in serving the needs of our customers in the region, which will ultimately benefit patients.”

Sanjay Kapote, President, India & Head, Pharma – SEA, said, “This new site in Mumbai provides a larger space, not only for the expansion of our well-established assembly operations, but also to fuel further localization and support our vision of bringing in other Aptar Pharma technologies suitable for the Asian market.”

Aptar Pharma Prescription President, Alex Theodorakis, commented on more than a decade of success for Aptar Pharma in India, which he described as both a key pillar in the pharma ecosystem and a new chapter of growth in the region.

In her virtual address, Xiangwei Gong, President, Aptar Asia, wholeheartedly congratulated the global and local Aptar Pharma teams for their tireless efforts that contributed to the completion of the Mumbai facility in just under two years.